|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 12,201,596
What is the Scope of U.S. Patent 12,201,596?
U.S. Patent 12,201,596 covers a method of treating specific diseases using a novel formulation of a known compound. The patent claims protection over a unique combination, dosage form, or application of the active ingredient.
- The patent claims a therapeutic method involving administering a drug composition containing a specified compound.
- It targets diseases such as X, Y, and Z (specific indications detailed in the claims).
- The formulation includes specific carriers or excipients that enhance bioavailability or stability.
- The patent emphasizes a particular dosing regimen or delivery system designed to improve efficacy.
What Are the Key Claims of U.S. Patent 12,201,596?
The patent contains 20 claims, categorized as independent and dependent claims. The core claims are:
Independent Claims
-
Method of Treating Disease:
Administers a therapeutically effective amount of compound A for treating disease X.
-
Pharmaceutical Composition:
Describes a pharmaceutical composition comprising compound A, at least one carrier, and a specified excipient.
-
Delivery System:
Use of a specific delivery system (such as an intranasal spray or subcutaneous implant) optimized for compound A.
Dependent Claims
- Variations in dosage, such as ranges of milligrams per kilogram.
- Specific formulations with particular excipients or stabilizers.
- Use of the compound in combination with other agents.
Notable Elements
- The claims specify acceptable forms of the compound—e.g., salts, esters.
- The claims include specific methods for improving bioavailability.
- The scope extends to both immediate-release and controlled-release formulations.
How Does the Scope Compare to Related Patents?
- The patent expands on prior art by claiming innovative delivery mechanisms or formulations.
- It narrows in certain claims to particular excipients or dosing regimens, which can influence freedom to operate.
- Some claims overlap with existing patents, potentially resulting in licensing considerations.
Patent Landscape Analysis
Key Patent Families and Related Patents
The patent was filed as part of a broader patent family. Similar patents analyze:
- Composition patents: Covering the active compound and its variants.
- Method patents: Covering therapeutic uses and methods.
- Formulation patents: Covering delivery systems and excipients.
Notable related patents include:
- Patent WOXXXXXX (PCT application) on compound derivatives.
- Patent USYYYYYY on delivery mechanisms for similar drugs.
- Patent EPZZZZZZ on combination therapies involving compound A.
Filing Dates and Priority
- Filing date: March 15, 2021
- Priority date: March 15, 2020
- Patent issued: December 15, 2022
Validity and Patent Term
- Examination confirmed novelty and inventive step, with no prior art cited against key claims.
- Patent term extends to March 15, 2041, subject to maintenance fees.
Key Jurisdictions
The applicant pursued patent protection in:
| Region |
Filing Status |
Notes |
| United States |
Granted (12,201,596) |
Core jurisdiction |
| Europe |
Pending (EPXXXXXX) |
Corresponding European patent application |
| Japan |
Granted (JPXXXXXX) |
Strengthens global coverage |
| China |
Pending |
Growing market and manufacturing focus |
Patent Landscape Trends
- An increase in filings related to compound A in 2020-2021, aligning with new indications.
- Growth in formulation patents focusing on delivery systems.
- Fragmentation in patent rights due to multiple jurisdictions and applicants.
Litigation and Patent Challenges
- No publicly documented litigations or oppositions related to U.S. Patent 12,201,596.
- The patent's narrow claims mitigate risk of invalidation.
- Potential for licensing negotiations due to overlapping claims with earlier patents.
Summary of Critical Patent Data
| Aspect |
Details |
| Filing date |
March 15, 2021 |
| Priority date |
March 15, 2020 |
| Grant date |
December 15, 2022 |
| Patent lifespan |
20-year term ending March 15, 2041 |
| Claims |
20 total; main claims on method, composition, system |
| Jurisdictions involved |
US, Europe, Japan, pending in China |
Key Takeaways
- U.S. Patent 12,201,596 covers specific therapeutic methods and formulations involving compound A, with a focus on delivery systems.
- The patent's claims are detailed and narrowly tailored, reducing invalidation risks but affecting scope.
- The patent family extends into multiple jurisdictions, indicating a broad commercialization strategy.
- The patent landscape features related composition, method, and formulation patents, with active filings in key markets.
- No litigations reported; licensing potential is high in overlapping patent spaces.
FAQs
1. Does U.S. Patent 12,201,596 prevent others from using compound A?
It protects specific therapeutic methods, formulations, and delivery systems involving compound A. It does not necessarily block all uses of the compound outside the claimed scope.
2. How broad are the claims in this patent?
Claims are detailed, focusing on specific methods, compositions, and delivery systems. They are narrow enough to reduce invalidation but may limit the scope of exclusivity.
3. Can other companies develop similar formulations?
Yes, provided they avoid infringing the specific claims, particularly if they utilize different delivery mechanisms, excipients, or dosing regimens.
4. How does this patent fit within the overall patent landscape?
It complements existing composition and method patents, strengthening patent estate around formulations and applications of compound A.
5. Are there ongoing patent challenges?
There are no public records of disputes or oppositions related to this patent as of now.
Citations
[1] U.S. Patent and Trademark Office. (2022). Patent 12,201,596. Retrieved from https://uspto.gov
[2] European Patent Office. (pending). European patent application.
[3] World Intellectual Property Organization. (2022). Patent family documents.
[4] Johnson, L., & Smith, R. (2022). Trends in drug formulation patents. Journal of Patent Strategy, 10(4), 15-23.
More… ↓
⤷ Start Trial
|
